| 2.09 -0.01 (-0.48%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.73 | 1-year : | 3.19 |
| Resists | First : | 2.33 | Second : | 2.73 |
| Pivot price | 2.09  |
|||
| Supports | First : | 1.86 | Second : | 1.57 |
| MAs | MA(5) : | 2.07 |
MA(20) : | 2.04 |
| MA(100) : | 2.37 |
MA(250) : | 2.87 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 49.8 |
D(3) : | 52 |
| RSI | RSI(14): 49.4 |
|||
| 52-week | High : | 6.78 | Low : | 1.57 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ VYNE ] has closed above bottom band by 48.3%. Bollinger Bands are 44.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.14 - 2.15 | 2.15 - 2.16 |
| Low: | 1.97 - 1.99 | 1.99 - 2 |
| Close: | 2.07 - 2.09 | 2.09 - 2.11 |
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Wed, 24 Jul 2024
VYNE Therapeutics (NASDAQ:VYNE) Shares Down 0.5% - Defense World
Tue, 16 Jul 2024
VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor - StockTitan
Tue, 16 Jul 2024
VYNE Therapeutics secures UK patent for inflammation drug - Investing.com
Thu, 11 Jul 2024
One VYNE Therapeutics Insider Raised Stake By 55% In Previous Year - Yahoo Finance
Tue, 09 Jul 2024
VYNE Therapeutics Appoints Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development - citybiz
Tue, 09 Jul 2024
VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 9.88e+006 (%) |
| Held by Institutions | 8.4 (%) |
| Shares Short | 51 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -7 % |
| Return on Assets (ttm) | 530.6 % |
| Return on Equity (ttm) | -30.3 % |
| Qtrly Rev. Growth | 423000 % |
| Gross Profit (p.s.) | -0.69 |
| Sales Per Share | -35.56 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -28 (M) |
| PE Ratio | 0 |
| PEG Ratio | -0.1 |
| Price to Book value | 0 |
| Price to Sales | -0.06 |
| Price to Cash Flow | 0.52 |
| Dividend | 0 |
| Forward Dividend | 55860 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|